Boundless Bio has announced it will not advance BBI-825 into the second part of the STARMAP clinical trial due to challenges related to emerging clinical data and the competitive landscape for ...
Third ecDTx program advancing, with plans for development candidate nomination by mid-2025 Operating runway extended into 2027, through anticipated clinical readout for BBI-355 and key development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback